Global Cell & Gene Therapy Manufacturing Services Market Size study & Forecast, by Type, Indication, Application, End User and Regional Forecasts 2025-2035

Description

The Global Cell & Gene Therapy Manufacturing Services Market, valued at approximately USD 7.04 billion in 2024, is projected to expand at a striking CAGR of 17.50% from 2025 to 2035. As the life sciences sector pushes the boundaries of modern medicine, cell and gene therapy manufacturing services have emerged as a vital bridge between groundbreaking research and large-scale therapeutic delivery. These specialized services encompass a broad spectrum of capabilities-from process development and viral vector production to commercial-scale manufacturing-enabling biopharmaceutical companies to accelerate the translation of advanced therapies into market-ready treatments. Increasing incidences of genetic disorders, a growing pipeline of cell and gene therapy candidates, and regulatory incentives for regenerative medicine are collectively propelling the market forward. Meanwhile, advancements in automation, closed-system manufacturing, and scalable bioprocessing platforms are redefining efficiency, cost-effectiveness, and global accessibility of these life-saving modalities.

The momentum within this market is further amplified by the exponential growth in oncology-focused therapies, with CAR-T and TCR-based treatments leading the charge. These transformative therapies demand highly controlled, GMP-compliant environments and expert handling, pushing pharmaceutical and biotech firms to seek specialized contract development and manufacturing organizations (CDMOs) with deep technical expertise. Moreover, the rise of allogeneic approaches promises to overcome the scalability and cost challenges associated with autologous therapies, broadening patient accessibility. As precision medicine gains wider adoption, demand for flexible manufacturing capacities capable of rapid scale-up for both clinical trials and commercial distribution is soaring. Industry collaborations, multi-site manufacturing footprints, and robust quality management systems are becoming non-negotiable for success in this rapidly evolving landscape.

Regionally, North America is anticipated to command the largest share of the market in 2025, bolstered by its strong biotechnology ecosystem, high concentration of clinical trials, and advanced regulatory frameworks that support expedited approval pathways for regenerative medicines. Europe continues to strengthen its position through substantial investments in manufacturing infrastructure, collaborative R&D networks, and supportive funding programs from the European Medicines Agency and national governments. Meanwhile, Asia Pacific is expected to witness the fastest growth over the forecast period, driven by increasing government investment in biotechnology hubs, the rise of contract manufacturing in countries like China, South Korea, and Singapore, and an expanding patient pool for genetic and oncology disorders. The region's growing capabilities in cost-efficient manufacturing, coupled with favorable regulatory reforms, are attracting global players to establish production partnerships and innovation centers in the region.

Major market players included in this report are:

Lonza Group AG
Catalent, Inc.
WuXi AppTec Co., Ltd.
Thermo Fisher Scientific Inc.
Samsung Biologics
Fujifilm Diosynth Biotechnologies
Bluebird Bio, Inc.
Oxford Biomedica plc
Boehringer Ingelheim International GmbH
Novartis AG
Takara Bio Inc.
BioNTech SE
Charles River Laboratories International, Inc.
Cell and Gene Therapy Catapult
Kite Pharma, Inc.

Global Cell & Gene Therapy Manufacturing Services Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Type:

Allogeneic
Autologous
Viral Vector
Non-viral Vector

By Indication:

Oncology
Orthopedic
Ophthalmology

By Application:

Clinical
Commercial

By End User:

Pharma
Biotech

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Cell & Gene Therapy Manufacturing Services Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study (Historical Data - 2023, 2024; Base Year for Estimation - 2024; Forecast period - 2025-2035)

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings

Chapter 3. Global Cell & Gene Therapy Manufacturing Services Market Forces Analysis

3.1. Market Forces Shaping The Global Cell & Gene Therapy Manufacturing Services Market (2024-2035)
3.2. Drivers
- 3.2.1. Rapid expansion of cell & gene therapy pipelines and increasing clinical trial activity driving CDMO demand
- 3.2.2. Regulatory incentives, expedited pathways and rising private & public investment in regenerative medicine manufacturing
3.3. Restraints
- 3.3.1. High capital expenditure, stringent GMP requirements and complex process development constraining new capacity build-out
- 3.3.2. Supply-chain bottlenecks for viral vectors, plasmids and raw materials plus skilled workforce shortages
3.4. Opportunities
- 3.4.1. Scaling allogeneic and non-viral platform technologies to reduce per-dose costs and enable commercial access
- 3.4.2. Geographic expansion (APAC & emerging biotech hubs) and contract manufacturing partnerships unlocking new capacity

Chapter 4. Global Cell & Gene Therapy Manufacturing Services Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Cell & Gene Therapy Manufacturing Services Market Size & Forecasts by Type 2025-2035

5.1. Market Overview
5.2. Global Cell & Gene Therapy Manufacturing Services Market Performance - Potential Analysis (2025)
5.3. Allogeneic
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Autologous
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. Viral Vector
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
5.6. Non-viral Vector
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Cell & Gene Therapy Manufacturing Services Market Size & Forecasts by Indication & Application 2025-2035

6.1. Market Overview
6.2. Global Cell & Gene Therapy Manufacturing Services Market Performance - Potential Analysis (2025)
6.3. Oncology
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Orthopedic
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Ophthalmology
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
6.6. Application: Clinical
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035
6.7. Application: Commercial
- 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.7.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Cell & Gene Therapy Manufacturing Services Market Size & Forecasts by Region 2025-2035

7.1. Cell & Gene Therapy Manufacturing Services Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Cell & Gene Therapy Manufacturing Services Market
- 7.3.1. U.S. Cell & Gene Therapy Manufacturing Services Market
  - 7.3.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.3.1.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.3.2. Canada Cell & Gene Therapy Manufacturing Services Market
  - 7.3.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.3.2.2. Indication & Application breakdown size & forecasts, 2025-2035
7.4. Europe Cell & Gene Therapy Manufacturing Services Market
- 7.4.1. UK Cell & Gene Therapy Manufacturing Services Market
  - 7.4.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.1.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.4.2. Germany Cell & Gene Therapy Manufacturing Services Market
  - 7.4.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.2.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.4.3. France Cell & Gene Therapy Manufacturing Services Market
  - 7.4.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.3.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.4.4. Spain Cell & Gene Therapy Manufacturing Services Market
  - 7.4.4.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.4.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.4.5. Italy Cell & Gene Therapy Manufacturing Services Market
  - 7.4.5.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.5.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.4.6. Rest of Europe Cell & Gene Therapy Manufacturing Services Market
  - 7.4.6.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.6.2. Indication & Application breakdown size & forecasts, 2025-2035
7.5. Asia Pacific Cell & Gene Therapy Manufacturing Services Market
- 7.5.1. China Cell & Gene Therapy Manufacturing Services Market
  - 7.5.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.1.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.5.2. India Cell & Gene Therapy Manufacturing Services Market
  - 7.5.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.2.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.5.3. Japan Cell & Gene Therapy Manufacturing Services Market
  - 7.5.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.3.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.5.4. Australia Cell & Gene Therapy Manufacturing Services Market
  - 7.5.4.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.4.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.5.5. South Korea Cell & Gene Therapy Manufacturing Services Market
  - 7.5.5.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.5.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.5.6. Rest of APAC Cell & Gene Therapy Manufacturing Services Market
  - 7.5.6.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.6.2. Indication & Application breakdown size & forecasts, 2025-2035
7.6. Latin America Cell & Gene Therapy Manufacturing Services Market
- 7.6.1. Brazil Cell & Gene Therapy Manufacturing Services Market
  - 7.6.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.6.1.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.6.2. Mexico Cell & Gene Therapy Manufacturing Services Market
  - 7.6.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.6.2.2. Indication & Application breakdown size & forecasts, 2025-2035
7.7. Middle East and Africa Cell & Gene Therapy Manufacturing Services Market
- 7.7.1. UAE Cell & Gene Therapy Manufacturing Services Market
  - 7.7.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.1.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Cell & Gene Therapy Manufacturing Services Market
  - 7.7.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.2.2. Indication & Application breakdown size & forecasts, 2025-2035
- 7.7.3. South Africa Cell & Gene Therapy Manufacturing Services Market
  - 7.7.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.3.2. Indication & Application breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Lonza Group AG
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. Catalent, Inc.
8.4. WuXi AppTec Co., Ltd.
8.5. Thermo Fisher Scientific Inc.
8.6. Samsung Biologics
8.7. Fujifilm Diosynth Biotechnologies
8.8. Bluebird Bio, Inc.
8.9. Oxford Biomedica plc
8.10. Boehringer Ingelheim International GmbH
8.11. Novartis AG
8.12. Takara Bio Inc.
8.13. BioNTech SE
8.14. Charles River Laboratories International, Inc.
8.15. Cell and Gene Therapy Catapult
8.16. Kite Pharma, Inc.